# Biosimilar User Fee Rates for Fiscal Year 2027

> Starting October 1, 2026, companies making biosimilar drugs will pay updated fees to the FDA for developing and getting approval for their products. These fees cover new drug deve...

- Canonical URL: [https://policyrisk.com/federal-register/2026-15346](https://policyrisk.com/federal-register/2026-15346)
- Route Path: `/federal-register/2026-15346`
- Route Type: `research-federal-register-document`

## Key Details
- Document Number: 2026-15346
- Publication Date: 2026-07-30T00:00:00.000Z
- Type: Notice
- Agencies: Health and Human Services Department, Food and Drug Administration
- Wallet Impact Flag: Yes

## Related Links
- [Federal Register Listing](https://policyrisk.com/federal-register)
- [Research Hub](https://policyrisk.com/research)